Walnuts and Healthy Aging
NCT01634841, Not applicable, Completed, Loma Linda University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Walnuts and Healthy Aging | ClinicalTrials.gov |
| NCT number | NCT01634841 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 708 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Loma Linda University | ClinicalTrials.gov |
| Conditions | Age Related Cognitive Decline, Age Related Macular Degeneration | ClinicalTrials.gov |
| Interventions | Walnuts, habitual diet | ClinicalTrials.gov |
| First posted | 2012-07-06 | ClinicalTrials.gov |
| Last updated | 2021-06-24 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes from baseline in global cognitive composite score | 2 years | The composite score will be calculated using the scores from the tests listed below. We will calculate the standardized scores of each test as the score of each participant minus the group mean and divide by its standard deviation. The composite score is the mean of the standardized scores. The 12 tests are: Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Complex Figure (ROCF), Semantic Fluency (Animals), Boston Naming Test (BNT), Visual Object and Space Perception Battery (VOSP), Block Design section from the Wechsler Adult Intelligence Scale (WAIS-III), Trail Making Test (TMT), FAS Word Fluency, Stroop Color Word Test, Symbol Digit Modalities Test (SMDT) Digit Span from the WAIS-III and Conners Continuous Performance Test (CPT-II). | ClinicalTrials.gov |
| Primary | Changes from baseline in macular degeneration | 2 years | This will be assessed: by stereoscopic digitized color fundus images graded by International Classification System for Age-Related Maculopathy (score range. 0 to 4; the higher the score, the worse the condition); by optical coherence tomography (OCT) measurements of macular thickness (in µm); by optical coherence tomography (OCT) measurements of retinal nervous fiber layer thickness (in µm). | ClinicalTrials.gov |
| Secondary | Change from baseline in brain cortical thickness | 2 years | Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mm2. | ClinicalTrials.gov |
| Secondary | Change from baseline in voxel-based morphometry | 2 years | Changes will be assessed by brain magnetic resonance imaging (MRI) using GM density maps on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is GM density. | ClinicalTrials.gov |
| Secondary | Change from baseline in white matter hyperintensity volumes | 2 years | Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is mL. | ClinicalTrials.gov |
| Secondary | Change from baseline in perfusion arterial spin labeling | 2 years | Changes will be assessed by brain magnetic resonance imaging (MRI) on a randomly selected subset of participants. Only in Barcelona center. Unit of measure is ml/100 g/min. | ClinicalTrials.gov |
| Secondary | Changes from baseline in brain activation | 2 years | Changes will be assessed by Functional MRI (fMRI) on a randomly selected subset of participants. Only in Barcelona center. There are no units of measure. | ClinicalTrials.gov |
| Other | Change in carotid Intima-media thickness (mm) | 2 years | Changes will be assessed by high-resolution ultrasound. Only in Barcelona center. | ClinicalTrials.gov |
| Other | Incidence of plaque presence in carotid artery (yes/no) | 2 years | Changes will be assessed by high-resolution ultrasound. Only in Barcelona center. | ClinicalTrials.gov |
| Other | Change in carotid atheroma plaque height (mm) | 2 years | Changes will be assessed by high-resolution ultrasound. Only in Barcelona center. | ClinicalTrials.gov |
| Other | Change in body mass index (kg/m2) | 2 years | BMI will be calculated as weight in kilograms divided by height in metres squared | ClinicalTrials.gov |
| Other | Change in waist circumference (cm) | 2 years | Waist circumference will be measured to the nearest 0.5 cm by using an anthropometric tape midway between the lowest rib and at the iliac crest at minimal respiration | ClinicalTrials.gov |
| Other | Change in total fat (g) | 2 years | Changes will be assessed by Dual-energy X-ray absorptiometry. Only in Barcelona center. | ClinicalTrials.gov |
| Other | Change in Total lean tissue (g) | 2 years | Changes will be assessed by Dual-energy X-ray absorptiometry. Only in Barcelona center. | ClinicalTrials.gov |
| Other | Change in fasting serum total cholesterol (mg/dL) | 2 years | Fasting serum total cholesterol will be measured by a standard enzymatic method | ClinicalTrials.gov |
| Other | Change in fasting serum LDL-cholesterol (mg/dL) | 2 years | Fasting serum LDL-cholesterol will be estimated by the Friedewald formula | ClinicalTrials.gov |
| Other | Change in fasting serum HDL-cholesterol (mg/dL) | 2 years | Fasting serum HDL-cholesterol will be measured by a precipitation technique | ClinicalTrials.gov |
| Other | Change in fasting serum triglycerides (mg/dL) | 2 years | Fasting triglycerides will be measured by a standard enzymatic method | ClinicalTrials.gov |
| Other | Change in serum brain-derived neurotrophic factor (pg/mL) | 2 years | Assessed by ELISA | ClinicalTrials.gov |
| Other | Change in serum soluble-Selectin (ng/mL) | 2 years | Assessed by ELISA | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 16
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 27535872 | DERIVED | PubMed |
| 27636672 | DERIVED | PubMed |
| 28119602 | DERIVED | PubMed |
| 29478886 | DERIVED | PubMed |
| 30879358 | DERIVED | PubMed |
| 30962275 | DERIVED | PubMed |
| 31912155 | DERIVED | PubMed |
| 32428300 | DERIVED | PubMed |
| 32827219 | DERIVED | PubMed |
| 33017652 | DERIVED | PubMed |
| 33236064 | DERIVED | PubMed |
| 33903255 | DERIVED | PubMed |
| 37365003 | DERIVED | PubMed |
| 38081585 | DERIVED | PubMed |
| 42373047 | DERIVED | PubMed |
| 42841852 | DERIVED | PubMed |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Primary outcome | ConductCognition |
| Complex Figure Copy and Recall | Primary outcome | ConductCognition |
| Continuous Performance Test | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.